Longitude Capital

Portfolio Companies 2026 for Longitude Capital: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Longitude Capital accounts for 33 tracked companies with verified cap-table data, 33 of which disclose round sizes totalling $7.5B. The median disclosed raise is $135M, and the largest is Vaxcyte at $2.4B, ahead of Somatus ($500M) and Nalu Medical ($396M).

The names that recur most often on these portfolio cap tables are Longitude Capital (33 companies), RA Capital Management (5 companies), Omega Funds (5 companies), Novo Holdings (4 companies), OrbiMed (4 companies), Decheng Capital (3 companies). By latest disclosed round, the market skews Series B (10), Series A (9), Series C (6), Series D (3).

Best funded Longitude Capital companies

  1. Vaxcyte — $2.4B (latest: IPO)
  2. Somatus — $500M (latest: Series E)
  3. Nalu Medical — $396M (latest: Growth)
  4. Alentis Therapeutics — $366M (latest: Series D)
  5. Talaris Therapeutics — $365M (latest: Other Equity)
  6. Endeavor BioMedicines — $292M (latest: Series A)
  7. CG Oncology — $200M (latest: IPO)
  8. Kestra Medical Technologies, Inc. — $196M (latest: Series C)
  9. Amunix — $193M (latest: Series B)
  10. Ceribell — $188M (latest: Series C)
  11. LEXEO Therapeutics — $185M (latest: Series B)
  12. cAMPfield Therapeutics — $180M (latest: Series A)
  13. Rivus Pharmaceuticals — $167M (latest: Series B)
  14. Tricida — $153M (latest: Series D)
  15. Quanta Therapeutics — $142M (latest: Series D)

Longitude Capital — related firms and companies (56)

Longitude Capital alternatives · All research reports